PFE
Income statement / Annual
Last year (2023), Pfizer Inc.'s total revenue was $58.50 B,
a decrease of 41.70% from the previous year.
In 2023, Pfizer Inc.'s net income was $2.12 B.
See Pfizer Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$58.50 B
|
$100.33 B
|
$81.29 B
|
$41.91 B
|
$51.75 B
|
$53.65 B
|
$52.55 B
|
$52.82 B
|
$48.85 B
|
$49.61 B
|
| Cost of Revenue |
$29.21 B |
$34.34 B |
$30.82 B |
$8.69 B |
$10.22 B |
$11.25 B |
$11.24 B |
$12.33 B |
$9.65 B |
$9.58 B |
| Gross Profit |
$29.28 B |
$65.99 B |
$50.47 B |
$33.22 B |
$41.53 B |
$42.40 B |
$41.31 B |
$40.50 B |
$39.20 B |
$40.03 B |
| Gross Profit Ratio |
0.5 |
0.66 |
0.62 |
0.79 |
0.8 |
0.79 |
0.79 |
0.77 |
0.8 |
0.81 |
| Research and Development
Expenses |
$10.58 B
|
$11.43 B
|
$13.83 B
|
$9.41 B
|
$8.65 B
|
$8.01 B
|
$7.66 B
|
$7.87 B
|
$7.69 B
|
$8.39 B
|
| General & Administrative
Expenses |
$10.77 B
|
$10.88 B
|
$10.70 B
|
$9.82 B
|
$12.05 B
|
$11.76 B
|
$11.68 B
|
$11.64 B
|
$11.71 B
|
$11.00 B
|
| Selling & Marketing
Expenses |
$3.70 B
|
$2.80 B
|
$2.00 B
|
$1.80 B
|
$2.30 B
|
$2.70 B
|
$3.10 B
|
$3.20 B
|
$3.10 B
|
$3.10 B
|
| Selling, General &
Administrative Expenses |
$14.47 B
|
$13.68 B
|
$12.70 B
|
$11.62 B
|
$14.35 B
|
$14.46 B
|
$14.78 B
|
$14.84 B
|
$14.81 B
|
$14.10 B
|
| Other Expenses |
$2.67 B |
$3.61 B |
$3.70 B |
$3.44 B |
$4.61 B |
$1.14 B |
$981.00 M |
$820.00 M |
$519.00 M |
$1.27 B |
| Operating Expenses |
$25.05 B |
$28.71 B |
$30.23 B |
$24.46 B |
$27.61 B |
$27.35 B |
$27.20 B |
$26.77 B |
$26.23 B |
$26.53 B |
| Cost And Expenses |
$54.26 B |
$63.06 B |
$61.05 B |
$33.15 B |
$37.83 B |
$38.60 B |
$38.44 B |
$39.09 B |
$35.88 B |
$36.11 B |
| Interest Income |
$1.62 B |
$251.00 M |
$36.00 M |
$73.00 M |
$226.00 M |
$333.00 M |
$391.00 M |
$470.00 M |
$471.00 M |
$425.00 M |
| Interest Expense |
$2.37 B |
$1.24 B |
$1.29 B |
$1.45 B |
$1.57 B |
$1.32 B |
$1.27 B |
$1.19 B |
$1.20 B |
$1.36 B |
| Depreciation &
Amortization |
$6.29 B
|
$5.06 B
|
$5.19 B
|
$4.68 B
|
$5.80 B
|
$6.38 B
|
$6.27 B
|
$5.76 B
|
$3.73 B
|
$4.04 B
|
| EBITDA |
$10.53 B
|
$43.64 B
|
$28.53 B
|
$14.07 B
|
$19.75 B
|
$21.41 B
|
$20.24 B
|
$19.08 B
|
$17.69 B
|
$19.23 B
|
| EBITDA Ratio |
0.18 |
0.43 |
0.35 |
0.34 |
0.38 |
0.4 |
0.39 |
0.36 |
0.36 |
0.39 |
| Operating Income Ratio
|
0.07
|
0.4
|
0.31
|
0.25
|
0.29
|
0.28
|
0.27
|
0.26
|
0.27
|
0.27
|
| Total Other
Income/Expenses Net |
-$3.18 B
|
-$5.30 B
|
-$522.00 M
|
-$3.13 B
|
$2.55 B
|
-$2.18 B
|
-$923.00 M
|
-$4.66 B
|
-$3.28 B
|
-$325.00 M
|
| Income Before Tax |
$1.06 B |
$34.73 B |
$24.31 B |
$7.50 B |
$17.68 B |
$11.89 B |
$12.31 B |
$8.35 B |
$8.97 B |
$12.24 B |
| Income Before Tax Ratio
|
0.02
|
0.35
|
0.3
|
0.18
|
0.34
|
0.22
|
0.23
|
0.16
|
0.18
|
0.25
|
| Income Tax Expense |
-$1.11 B |
$3.33 B |
$1.85 B |
$477.00 M |
$1.38 B |
$706.00 M |
-$9.05 B |
$1.12 B |
$1.99 B |
$3.12 B |
| Net Income |
$2.12 B |
$31.37 B |
$21.98 B |
$7.02 B |
$16.27 B |
$11.15 B |
$21.31 B |
$7.22 B |
$6.96 B |
$9.14 B |
| Net Income Ratio |
0.04 |
0.31 |
0.27 |
0.17 |
0.31 |
0.21 |
0.41 |
0.14 |
0.14 |
0.18 |
| EPS |
0.38 |
5.59 |
3.95 |
1.26 |
2.92 |
1.9 |
3.57 |
1.18 |
1.13 |
1.44 |
| EPS Diluted |
0.38 |
5.47 |
3.88 |
1.25 |
2.87 |
1.87 |
3.52 |
1.17 |
1.11 |
1.42 |
| Weighted Average Shares
Out |
$5.64 B
|
$5.61 B
|
$5.60 B
|
$5.56 B
|
$5.57 B
|
$5.87 B
|
$5.97 B
|
$6.09 B
|
$6.18 B
|
$6.35 B
|
| Weighted Average Shares
Out Diluted |
$5.71 B
|
$5.73 B
|
$5.71 B
|
$5.63 B
|
$5.68 B
|
$5.98 B
|
$6.06 B
|
$6.16 B
|
$6.26 B
|
$6.42 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
